JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions

NORTHBROOK, Ill., April 19, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced that new data for JATENZO (testosterone undecanoate) will be presented in the form of two abstracts at the Androgen Society 4th Annual Meeting taking place at the JW Marriott Bonnet Creek in Orlando, Florida, April 21-23, 2022.

Details on the abstract presentations for JATENZO are below.

Abstract Title: Relationship Between Time of Testing and 24-Hour Average Concentration of Total Testosterone in Hypogonadal Men Treated with an Oral Testosterone Undecanoate Capsule (JATENZO) Date/time: Saturday, April 23, 10:15 a.m. – 10:20 a.m. EDT Session: Abstract Session 1

Abstract Title: Comparison Between Oral Testosterone Undecanoate (JATENZO) and a Transdermal Testosterone Gel (AndroGel 1%) in Total Testosterone, Free Testosterone and SHBG After One Year of Therapy Date/time: Saturday, April 23, 10:20 a.m. – 10:25 a.m. EDT Session: Abstract Session 1

About Male Hypogonadism Male hypogonadism is a condition that results when the testes do not produce enough testosterone. Symptoms associated with male hypogonadism can include depression, decreased sex drive, decreased muscle mass, and decreased bone density, among others. An estimated 20 million men in the United States have hypogonadism, with approximately six million patients diagnosed. Treatments for male hypogonadism may include testosterone replacement therapy.

About Clarus Therapeutics Holdings, Inc. Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus’ first commercial product is JATENZO® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

JATENZO® is a registered trademark of Clarus Therapeutics Holdings, Inc.

Clarus Contact: Kara Stancell Vice President, Investor Relations & Corporate Communications kstancell@clarustherapeutics.com (847) 562-4300 x 206

Indication JATENZO® (testosterone undecanoate) capsules, CIII, is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.

Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitation of use Safety and efficacy of JATENZO in males less than 18 years old have not been established.

WARNING: INCREASES IN BLOOD PRESSURE

JATENZO can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death.

Before initiating JATENZO, consider the patient’s baseline cardiovascular risk and ensure blood pressure is adequately controlled.

Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of JATENZO outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment.

Due to this risk, use JATENZO only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies.

CONTRAINDICATIONS JATENZO is contraindicated in men with breast cancer or known or suspected prostate cancer. JATENZO is contraindicated in women who are pregnant as testosterone may cause fetal harm.

Check hematocrit prior to initiation and every 3 months while a patient is on JATENZO and if hematocrit becomes elevated, stop JATENZO until hematocrit decreases to an acceptable level. If hematocrit increases after JATENZO is restarted, stop permanently.

Monitor patients with benign prostatic hyperplasia (BPH) treated with androgens due to an increased risk for worsening signs and symptoms of BPH.

Venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone replacement products like JATENZO. Evaluate patients with signs or symptoms consistent with DVT or PE and, if a VTE is suspected, discontinue JATENZO and initiate appropriate workup and management.

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids.

Large doses of androgens can suppress spermatogenesis by feedback inhibition of pituitary FSH. Inform patients of this risk before prescribing JATENZO.

Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse events. JATENZO is not known to cause these adverse events; however, patients should be instructed to report any signs of hepatic dysfunction and JATENZO should be discontinued while the cause is evaluated.

Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

Gynecomastia may develop and persist in patients being treated for hypogonadism.

Sleep apnea may occur in some patients, especially those with risk factors such as obesity or chronic lung disease.

Changes in the serum lipid profile may require dose adjustment of lipid-lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

Use JATENZO with caution in cancer patients at risk of hypercalcemia. Monitor serum calcium concentration regularly during treatment with JATENZO in these patients.

Androgens, including JATENZO, may decrease concentrations of thyroxine-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Depression and suicidal ideation have been reported in patients treated with JATENZO in clinical trials.

ADVERSE EVENTS The most common adverse events of JATENZO (incidence ≥2%) are headache (5%), increased hematocrit (5%), hypertension (4%), decreased HDL (3%), and nausea (2%).

These are not all of the risks associated with JATENZO. For more information, click here for full Prescribing Information, including BOXED WARNING on increases in blood pressure. You can also obtain information regarding JATENZO at www.jatenzo.com.

© 2022 Clarus Therapeutics, Inc. All rights reserved.

Diversification isn't necessary if you know what you're doing, according to the Oracle of Omaha.

Yahoo Finance's Akiko Fujita discusses why Roku stock is down Friday.

Airline ticket prices have soared. It is in this context that Elon Musk, CEO of Tesla has just made observations that will cheer almost everyone: consumers, Tesla customers, investors and politicians. In a series of tweets posted on July 28, Musk announced that the prices of the raw materials Tesla needs to make its cars are falling.

The company's future is in doubt after losing a key patent litigation

British American Tobacco p.l.c.'s ( LON:BATS ) investors are due to receive a payment of £0.5445 per share on 10th of...

In this article, we discuss the 7 stocks that Cathie Wood dumped in July. If you want to see more stocks that she disposed of during this month, click Cathie Wood Dumped These 3 Stocks in July. In June, Cathie Wood’s ARK Investment Management suffered a sharp decline in assets, which was decidedly higher than […]

Slaying the inflation dragon isn't done with baby steps. Expect much higher interest rates as a headwind for equities.

The oil giant is expected to have made far more than twice of what it pocketed in profit a year ago.

When Elon Musk decided to terminate his $44 billion deal to purchase Twitter the social-media company sued in the Delaware Court of Chancery. Twitter is suing for “specific performance,” a rare remedy that would require Musk to complete the merger. Unfortunately for Twitter, it isn’t Elon Musk Inc. but Elon Musk the individual who offered to buy the company.

Citi Global Chief Economist Nathan Sheets speaks with Yahoo Finance Live about inflation, global recession risks, central bank policies, and more.

Here’s a good bit of news for retirees in 2022: you can keep more money in your tax-deferred retirement accounts.

(Bloomberg) -- Alibaba Group Holding Ltd. has moved a step closer toward getting booted off US stock exchanges for American inspectors not being able to access to financial audits.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekAlito Decries 'Hostility to Religion' in First Public Remarks Since Abortion Decision Rockstar Games Cleaned Up Its Frat-Boy Culture — and Grand Theft Auto, TooBiden, Xi Plan In-Person Meet as Taiwan Tensions IntensifyEuro-Zone Infla

The company is making progress on its solid-state battery technology, but the timeline has been pushed back.

V.F. Corp's (VFC) first-quarter fiscal 2023 results reflect lower earnings. Nevertheless, revenues rose on solid consumer engagement with its outdoor, streetwear and active brands.

Shares of Plug Power (NASDAQ: PLUG), a hydrogen fuel cell company, skyrocketed this week as investors processed the news that Sen. Joe Manchin, the West Virginia Democrat, would support the Inflation Reduction Act of 2022, which includes investments in alternative energy, including hydrogen. Democrats needed Manchin's support for the bill, which includes $369 billion for clean energy and other climate initiatives. The Senate could vote on the bill as early as next week, and then it would go to the House for approval, which could vote on the legislation in early August.

(Bloomberg) -- With recession fears mounting—and inflation, the war in Ukraine and the lingering pandemic taking a toll—many tech companies are rethinking their staffing needs, with some of them instituting hiring freezes, rescinding offers and making rounds of layoffs.Most Read from BloombergThe Crypto Collapse Has Flooded the Market With Rolex and PatekAlito Decries 'Hostility to Religion' in First Public Remarks Since Abortion Decision Rockstar Games Cleaned Up Its Frat-Boy Culture — and Gran

Yahoo Finance autos correspondent Pras Subramanian joins the Live show to detail the latest tax credit Senate passed to promote EV adoption.

DraftKings (DKNG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Advanced Micro Devices' (AMD) second-quarter 2022 performance is likely to have benefited from the momentum in the adoption of semi-custom and EPYC server processors.

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...